The product, Elute’s EP Granules with Tobramycin, is a synthetic bone filler that provides an eight-week delivery of an antibiotic while allowing bone growth, according to a Nov. 30 news release. Orthopedic surgeons Amar Ranawat, MD, of HSS and Javad Parvizi, MD, of Rothman are clinical partners in the trial.
The trials come after EP Granules with Tobramycin received investigational device exemption authorization from the FDA.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
